Article Text
PDF
Abstract
Background Only few studies have compared health related quality of life (HRQoL) between rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients.
Objectives To compare the Medical Outcomes Survey Short Form-36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) in RA and PsA patients from a large prospective observational registry.
Methods We included RA and PsA patients from the prospective observational multicenter Norwegian-Disease-Modifying Antirheumatic Drug (NOR-DMARD) study, who started first-time tumour necrosis factor inhibitors or DMARD naïve patients starting methotrexate between year 2000 and 2012. Continuous variables were compared using independent t-test (normally distributed data). Prespecified ANCOVA analyses adjusted for age, gender and years since diagnosis were performed to compare SF-36 PCS and MCS between the RA and PsA patients at baseline and after 3 and 6 months follow-up.
Results A total of 2735 RA and 1236 PsA patients were included. Mean (SD) age was 55.0 (13.5)/ 48.3 (12.4) years, median (25th-75th percentile) years since diagnosis 0.7 (0.02–6.4)/ 1.3 (0.09–7.7), 69.7/48.4% were women and 31.7/29.8% current smokers. Mean (SD) 28-joint Disease Activity Score was higher in RA vs. PsA patients at baseline (4.9 (1.4)/ 4.2 (1.3)) and at 3 (3.6 (1.5)/ (3.1 (1.4)) and 6 months follow-up (3.3 (1.4)/ 3.0 (1.3)), respectively (p≤0.001). Unadjusted means (SD) of SF-36 PCS and MCS were similar between the RA and PsA patients (Table 1).
Unadjusted means (SD) of SF-36 PCS and MCS
In adjusted analyses SF-36 PCS was slightly higher and SF-36 MCS similar between RA and PsA patients at 3 and 6 months follow-up (Table 2).
ANCOVA analyses with adjustment for age, gender and years since diagnosis
Conclusions Mental HRQoL reflected through SF-36 MCS was similar between RA and PsA patients at all time points, in spite of slightly worse physical HRQoL reflected through lower SF-36 PCS in the PsA group at 3 and 6 months follow-up.
Disclosure of Interest B. Michelsen: None declared, E. Lie Consultant for: Hospira, Pfizer, UCB, Speakers bureau: AbbVie, Celgene, K. Fagerli: None declared, E. Kristianslund: None declared, H. Hammer Consultant for: AbbVie, Pfizer, UCB, Roche, MSD, BMS and Novartis., Speakers bureau: AbbVie, Pfizer, UCB, Roche, MSD, BMS and Novartis., G. Haugeberg: None declared, T. Kvien Consultant for: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Epirus, Janssen, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz and UCB, Speakers bureau: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Epirus, Janssen, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz and UCB